Furthermore, tumour growth decreased in the mutant PIK3CA–PDX model following administration of GSK112012 (3 mg/kg) and NVP-TNKS656 (50 mg/kg), the latter of which targets the WNT pathway (Fig. 5f). The gene discussed is PIK3CA; the disease is neoplasm.